MDMX Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of MDMX Antibodies for investigating MDMX in cellular processes. MDMX Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). MDMX, also known as MDM4, is a critical regulator of the p53 tumor suppressor pathway, playing a significant role in cell cycle regulation and apoptosis. By inhibiting p53, MDMX contributes to the development of various cancers, making it an important target for therapeutic intervention. Understanding MDMX function is essential for elucidating mechanisms of tumorigenesis and developing potential cancer treatments. MDMX research has revealed important insights into cancer development and progression. Ongoing studies continue to uncover new aspects of MDMX regulation and its impact on cellular pathways. Current research focuses on targeting MDMX as a therapeutic strategy in cancer treatment. Santa Cruz Biotechnology monoclonal antibodies for MDMX support researchers worldwide in advancing cancer biology understanding and therapeutic development.